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The interaction between menin and oncogenic mixed lineage leukemia (MLL) fusion proteins is required for
leukemic transformation andmay represent a therapeutic opportunity. In this issue ofCancer Cell, Borkin and
colleagues describe the development of highly potent small-molecule inhibitors of this interaction that
reverse the leukemic phenotype and prolong survival in murine models of MLL-rearranged leukemia.Acute leukemias that harbor a rearrange-
ment of the mixed lineage leukemia gene
(MLL) are aggressive hematopoietic
malignancies that occur across all age
groups and develop as lymphoid,
myeloid, or biphenotypic disease. In in-
fants and children, MLL-rearranged leu-
kemias represent a poor risk category of
acute lymphoblastic leukemia. Adults
typically present with acute myeloid leu-
kemia that arises de novo or following
treatment with topoisomerase-II inhibitors
for an unrelated neoplastic disorder.
Chemotherapy is considered the stan-
dard of care, but treatment outcome is still
unsatisfactory with event-free survival
rates of approximately 50% for both pedi-
atric and adult patients (Neff and Arm-
strong, 2013). These data together with
the increasing population of older leuke-
mia patients not eligible for intensive
chemotherapy indicate a strong need for
novel less toxic treatment approaches.
Research over the last decade has sub-
stantially improved our understanding of
MLL-rearranged leukemogenesis and
disease biology. To date, more than 70
translocations are known that encode
dominant oncogenic fusion proteins
where MLL is fused to one of more than60 different partner proteins (Meyer
et al., 2013). Recent efforts have led to
the discovery of several potential molecu-
lar targets for therapeutic development.
The histone 3 lysine 79 methyltransferase
DOT1L and menin, a protein that interacts
directly with MLL-fusion proteins, repre-
sent two of the most well-characterized
candidates (Bernt et al., 2011; Yokoyama
et al., 2005). Both proteins are believed to
be required for MLL-fusion target gene
expression and transformation by MLL-
fusion proteins. Small-molecule DOT1L
inhibitors have recently been translated
to clinical trials (Daigle et al., 2013). In
this issue of Cancer Cell, Borkin et al.
(2015) describe the development of two
improved inhibitors of the menin-MLL
interaction that will hopefully enable
translation of this therapeutic approach
to clinical assessment.
Menin, the protein encoded by the mul-
tiple endocrine neoplasia 1 gene (Men1)
functions as a tumor suppressor in the
similarly-named familial syndrome but
contributes to MLL-rearranged leukemia
as a co-factor essential for leukemic
transformation (Yokoyama et al., 2005).
It interacts with the N-terminal part of
MLL, which is maintained in all MLL-fusion proteins, and is essential for MLL-
fusion-driven leukemogenesis. Inactiva-
tion of Men1 prevents leukemogenesis in
bone marrow progenitor cells ectopically
expressing MLL fusions (Chen et al.,
2006) and loss-of-function mutations in
the menin binding motif of MLL abrogate
leukemogenic transformation by MLL-
fusion proteins (Chen et al., 2006; Yo-
koyama et al., 2005). Menin is obligatory
for the interaction of MLL-fusion proteins
with LEDGF, a protein that facilitates
chromatin binding of the MLL complex
(Yokoyama and Cleary, 2008). Further-
more, the menin-MLL interaction is
required for the activation of MLL-fusion
target genes, such as Hoxa-cluster genes
andMeis1, which are pivotal for the devel-
opment of MLL-fusion-driven leukemia
(Yokoyama et al., 2005). However, reports
that the interaction between menin and
the wild-type MLL protein is required for
Hox gene expression in early hematopoi-
etic progenitors to maintain self-renewal
properties (Chen et al., 2006; Maillard
et al., 2009) raises the concern that thera-
peutic targeting of menin might lead to a
rapid attrition of hematopoietic stem cells,
thereby affecting normal hematopoiesis.
However a recent study by Li et al.l 27, April 13, 2015 ª2015 Elsevier Inc. 431
Figure 1. Inhibiting the Menin-MLL Interaction Causes Hox Gene
Downregulation and Differentiation of MLL-Rearranged Leukemia
(A) The menin-MLL interaction is required for Hox gene expression that is crit-
ical for MLL-rearranged leukemia.
(B) Small-molecule MI-463 and MI-503 block the MLL binding site on menin,
resulting in downregulation ofHox genes and differentiation of leukemic blasts.
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and the wild-type MLL also
control the expression of
unique sets of genes, indi-
cating the possibility of a
therapeutic index for inhibi-
tion of the menin-MLL inter-
action. Due to the lack of
specific small-molecule in-
hibitors suitable for in vivo
experiments, formal assess-
ment of these concepts has
been difficult.
In the current study, the
newly developed menin-MLL
inhibitors build on a previ-
ously reported thienopyrimi-
dine small molecule. Prior
studies from this group led
to the development of the
first inhibitors of this inter-
action that exhibited anti-
leukemic effects in models
of MLL-rearranged leukemia
in vitro. However, these earlycompounds were not adequate for
detailed in vivo studies due to moderate
cellular potency and poor pharmacoki-
netic properties. Using an elegant medic-
inal chemistry approach, Borkin and co-
workers gradually increased the potency
of the original compound by first modi-
fying the molecular scaffold and subse-
quent optimization of the binding affinity
to menin. These efforts resulted in two
small molecules, MI-463 and MI-503,
with high binding affinity and metabolic
stability. Pharmacokinetic studies in
mice revealed a favorable profile including
high oral bioavailability of 45% and 75%,
respectively. Treatment of murine and
human models of MLL-rearranged leuke-
mia with MI-463 and MI-503 in vitro
resulted in substantial growth inhibition
at sub-micromolar concentrations. The
authors assessed global gene expression
following menin-MLL inhibition and
observed the reversal of an MLL-fusion-
associated gene expression program
that included downregulation of the well-
defined MLL-fusion target genes Hoxa9
and Meis1. Gene expression changes
were associated with subsequent induc-
tion of myeloid differentiation (Figure 1)
and, to a lesser degree, apoptosis in
MLL-rearranged leukemia cells. In vivo
treatment also led to downregulation of
Hox genes after 20 days of menin-MLL
inhibition and resulted in a substantial432 Cancer Cell 27, April 13, 2015 ª2015 Elssurvival benefit for the treated animals.
A limited number of MLL-rearranged
primary patient samples also exhibited
decreased clonogenic potential in colony
forming assays in vitro, whereas other
leukemia subtypes failed to respond to
the treatment. Toxicity assessment re-
vealed no impairment of normal murine
hematopoiesis in non-leukemic mice or
any apparent organ toxicity after 10 days
of continuous menin-MLL inhibition. Spe-
cifically, the authors did not detect any
effect on overall bone marrow cellularity,
number of lineage-negative, Sca1+, Kit+
cells, or long-term hematopoietic stem
cells.
The present study provides critical
evidence that pharmacological inhibition
of the menin-MLL interaction may be a
promising therapeutic approach for the
treatment of MLL-rearranged leukemia.
Pharmacological insufficiency with regard
to in vivo utility as reported for the first
menin-MLL inhibitors has often been an
important hurdle in drug development.
Overcoming this problem as described
here is therefore a major step toward
future clinical application. Whereas
MLL-fusion proteins are difficult to target
directly, the interruption of this protein
interaction reverses Hox gene and
Meis1 expression, thereby releasing
the differentiation block associated with
MLL-rearranged leukemia cells. Whetherevier Inc.menin might also be required
for Hox gene expression
in selected non-MLL-rear-
ranged leukemias and
whether pharmacologic inter-
ruption of the menin-wild-
type MLL interaction might
have broader implications for
leukemia treatment remains
to be determined. Prior
concerns that inhibition of
menin-MLL interaction might
cause exhaustion of the
normal hematopoietic stem
cell pool were not observed
in this study, but it should be
noted that toxicity needs to
be assessed after treatment
for longer periods of time
to truly assess potential he-
matopoietic toxicity.
Finally, the study by Borkin
et al. (2015) represents
an important step toward
another possible targetedtherapy for MLL-fusion leukemia. Both
compounds synthesized in this study
are promising candidates for further
evaluation and potential prototypes for
compounds that could be introduced into
clinical trials. Furthermore, the develop-
ment of the small molecules described
here will prompt in vivo assessment of
combinations with other recently devel-
oped therapeutic approaches such as
DOT1L or bromodomain inhibitors. There
is increasing excitement that the rapid
pace of discovery we are witnessing in
the MLL-leukemia field will soon impact
patient outcome.ACKNOWLEDGMENTS
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In a recent issue ofNatureGenetics, Andersson and colleagues report thatMLL fusion alonemay be sufficient
to spawn an aggressive leukemia in infants. Some other pediatric cancers may share a similar, single, ‘‘big-
hit’’ origin, possibly reflecting a critical developmental window of stem cell vulnerability.Acute leukemias in infants are rare but
highly malignant and clinically intransi-
gent (Biondi et al., 2000). The majority of
leukemias have phenotypic features of
early or pro-B cells and recurrent rear-
rangements of MLL, predominantly as
chimeric gene fusions with AF4 (aka
AFF1) (Biondi et al., 2000).
Monozygotic twin infant pairs with
concordant acute lymphoblastic leuke-
mia (ALL) share an identical but non-
constitutive MLL genomic rearrangement
indicative of a single cell in utero origin
and progeny cell transfer via intra-
placental anastomoses (Greaves et al.,
2003). In non-twinned infants with ALL,
theMLL genomic sequence is detectable
in archived neonatal blood spots, sug-
gesting a pre-natal origin for most
patients (Gale et al., 1997). The concor-
dance rate for ALL in identical twin infants
with a monochorionic, or single placenta
is close to 100%. This, coupled with
the very short pre-clinical latency, has
suggested that MLL fusion might by
itself be sufficient for leukemia (Greaves
et al., 2003). Data from whole genome
sequencing of three cases of infant ALL
with MLL-AF4 fusion were compatible
with this notion (Dobbins et al., 2013). In
contrast, older children with B cell pre-cursor driven by ETV6-RUNX1 fusion or
hyperdiploidy also have a predominantly
in utero origin, but a requirement for addi-
tional post-natal mutations and a concor-
dance rate of 15% (Greaves et al.,
2003).
At face value, this possibility of a
single driver mutation conflicts with the
conventional notion that multiple and
sequential genetic changes need to be
accrued for a malignant phenotype to
emerge. In a recent publication, Ander-
sson et al. (2015) reported a detailed
genomic scrutiny of 22 cases of infant
ALL with MLLR (rearrangements). They
provided convincing evidence that MLL
gene fusion is the only detectable
genome-wide abnormality that is present
in all the cells. Other mutations are
present, particularly in the P13K-RAS
signaling pathway, but these are sub-
clonal (allele frequencies < 30%) and
not always retained in relapse. Older
children with MLL rearranged ALL had
more complex mutational landscapes.
These data suggest that, although
additional ‘‘driver’’ mutations occur
in infant ALL, the initiating lesion MLL
fusion is probably sufficient in itself to
spawn a large malignant clone (patients
with MLLR ALL have very high tumorburdens or white cell counts; Biondi
et al., 2000).
This important finding is not unique
to infant leukemia. In highly malignant
pediatric rhabdoid tumors, the only
discernible and recurrent exomic genetic
aberration is mutation and/or deletion,
leading to homozygous loss of function
in SMARCB1 (Lee et al., 2012). Paediatric
brain ependymomas subtypes are very
malignant but have remarkably silent
genomic landscapes with only one ge-
netic alteration: C11orf95-RELA fusion
found in most supratentorial ependymo-
mas (Parker et al., 2014). Other hindbrain
(posterior-fossa, group B) ependymomas
have no recurrent single nucleotide
variants, but large-scale copy number
changes (or aneuploidy) were present
along with genome-wide epigenetic
(methylation) changes (Mack et al.,
2014). It is possible that the sequencing
technologies employed in these studies
missed some cryptic mutational changes,
particularly in non-coding regions. Addi-
tionally, germline or constitutive genetic
variants may have contributed, epistat-
istically, to malignant transformation.
These caveats aside, the data collectively
argue that signal mutations can, excep-
tionally, have a major impact on cellularl 27, April 13, 2015 ª2015 Elsevier Inc. 433
